MC
DGX icon

Moors & Cabot’s Quest Diagnostics DGX Stock Holding History

Moors & Cabot’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$421K Sell
1,984
-132
-6% -$25.9K 0.02% 621
2026
Q1 		$415K Sell
2,116
-548
-21% -$106K 0.02% 595
2025
Q4 		$462K Buy
2,664
+439
+20% +$79.9K 0.02% 562
2025
Q3 		$424K Buy
+2,225
New +$395K 0.02% 568
2024
Q1 		– Sell
-18,045
Closed -$2.49M – 931
2023
Q4 		$2.49M Buy
18,045
+260
+1% +$34.2K 0.16% 138
2023
Q3 		$2.17M Sell
17,785
-429
-2% -$57.2K 0.15% 140
2023
Q2 		$2.56M Sell
18,214
-1,540
-8% -$212K 0.17% 131
2023
Q1 		$2.79M Sell
19,754
-377
-2% -$53.9K 0.19% 118
2022
Q4 		$3.15M Hold
20,131
– – 0.22% 107
2022
Q3 		$2.47M Buy
20,131
+29
+0.1% +$3.82K 0.19% 119
2022
Q2 		$2.67M Sell
20,102
-152
-0.8% -$20.7K 0.19% 115
2022
Q1 		$2.77M Sell
20,254
-109
-0.5% -$15.2K 0.17% 127
2021
Q4 		$3.52M Buy
20,363
+124
+0.6% +$18.9K 0.22% 100
2021
Q3 		$2.94M Buy
20,239
+5,522
+38% +$808K 0.19% 118
2021
Q2 		$1.94M Buy
+14,717
New +$1.93M 0.14% 158
2017
Q3 		– Sell
-1,995
Closed -$222K – 542
2017
Q2 		$222K Buy
+1,995
New +$211K 0.04% 447
2016
Q4 		– Sell
-2,753
Closed -$234K – 552
2016
Q3 		$234K Sell
2,753
-144
-5% -$12.1K 0.04% 439
2016
Q2 		$233K Buy
+2,897
New +$221K 0.04% 424
2016
Q1 		– Sell
-2,885
Closed -$205K – 531
2015
Q4 		$205K Buy
+2,885
New +$194K 0.04% 441
2015
Q2 		– Sell
-3,083
Closed -$239K – 533
2015
Q1 		$239K Sell
3,083
-210
-6% -$15K 0.04% 426
2014
Q4 		$217K Buy
+3,293
New +$208K 0.04% 435

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Moors & Cabot's DGX Position: Q2 2026 in Review

Moors & Cabot reduced its Quest Diagnostics (DGX) stake by 6.2% in Q2 2026, selling an estimated $25.9K and leaving 1,984 shares worth $421K. The position accounts for 0.02% of the portfolio, ranked #621.

Moors & Cabot first reported a position in DGX in Q4 2014 and has held it in 21 quarters since. The position peaked at $3.52M in Q4 2021. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Moors & Cabot held 1,984 shares of Quest Diagnostics worth $421K as of Q2 2026.
  • Moors & Cabot sold 132 Quest Diagnostics shares in Q2 2026, an estimated $25.9K.
  • Quest Diagnostics made up 0.02% of Moors & Cabot's portfolio in Q2 2026, its #621 holding.
  • Moors & Cabot first reported a position in Quest Diagnostics in Q4 2014 and has held it in 21 quarters since.
  • Moors & Cabot's Quest Diagnostics position peaked at $3.52M in Q4 2021.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.